News and Trends 17 Mar 2023
67% five-year survival rate in glioblastoma therapy, according to CANbridge Pharmaceuticals study
CANbridge Pharmaceuticals Inc. has announced that its therapy for glioblastoma has shown a 67% survival rate at five years, three years after the clinical trials ended. Four out of nine of the patients with newly diagnosed glioblastoma multiforme (GBM) who were part of the clinical study were reported to be alive three years after the […]